Latest News and Press Releases
Want to stay updated on the latest news?
-
Lund den 17 maj, 2010 - Den vetenskapliga tidskriften Molecular Cancer (doi:10.1186/1476-4598-9-107) har publicerat en artikel* avseende Active Biotechs (NASDAQ OMX Nordic: ACTI) prostatacancerprojekt...
-
Lund, Sweden, May 17, 2010 - Molecular Cancer (doi:10.1186/1476-4598-9-107) has published an article* covering Active Biotech's (NASDAQ OMX Nordic: ACTI) prostate cancer project TASQ, where...
-
Lund, Sweden, May 17, 2010 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present today at the Rodman & Renshaw 6th Annual Global Healthcare Conference at the Grosvenor House Hotel in...
-
Lund, Sweden, May 17, 2010 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present today at the Rodman & Renshaw 6th Annual Global Healthcare Conference at the Grosvenor House Hotel in...
-
The Annual General Meeting of Active Biotech was held on May 6, 2010. In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid. In accordance with the...
-
Active Biotechs årsstämma hölls den 6 maj 2010. I enlighet med styrelsens förslag beslöts att ingen utdelning skulle lämnas. I enlighet med valberedningens förslag omvaldes styrelseledamöterna...
-
The number of shares and votes in Active Biotech has changed as a result of the exercise of employee stock options and the directed share issue placed with funds managed by Sectoral Asset...
-
Antalet aktier och röster i Active Biotech har förändrats på grund av utnyttjande av personaloptioner samt den riktade nyemissionen till fonder förvaltade av Sectoral Asset Management Inc. Idag,...
-
· Laquinimod ― Teva extends its marketing and distribution rights for laquinimod · TASQ ― preparations for Phase III trials under way · ANYARA ― exploratory...
-
· Laquinimod ― Teva förvärvat ytterligare rättigheter i marknads- och distributionsavtalet för laquinimod · TASQ ― förberedelser för fas III-studier pågår · ANYARA ―...